TNFRSF17 and plasma cell myeloma: These proteins are currently being evaluated as therapeutic targets in oncology: (1) in the field of solid tumors for Netrin‐1, which is thought to be involved in the tumorigenesis of numerous carcinomas [1, 5, 6, 7]; and (2) in multiple myeloma (MM) for BCMA [3].